ESR1 and breast cancer: In this trial, 165 postmenopausal women with previously untreated ER-positive, HER2-negative advanced breast cancer received palbociclib plus letrozole or letrozole alone until disease progression, toxicity, withdrawal, or death (Finn et al., 2015).